

# UNITED STATES PATENT AND TRADEMARK OFFICE

IL

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/091,062	03/05/2002	Li-Lan H. Chen	366325-524	8011
	7590 09/22/2004		EXAMINER	
DECHERT LLP (WASHINGTON, DC OFFICE) 1775 I STREET, NW			CHOI, FRANK I	
WASHINGTON, DC 20006			ART UNIT	PAPER NUMBER
			1616	
			DATE MAILED: 09/22/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
		10/091,062	CHEN ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Frank I Choi	1616			
Period f	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
A SH THE - Exte after - If the - If NO - Failu Any	MORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. ensions of time may be available under the provisions of 37 CFR 1.13 r SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period we use to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing led patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be timed within the statutory minimum of thirty (30) day, will apply and will expire SIX (6) MONTHS from cause the application to become ARANDONE.	nely filed s will be considered timely. the mailing date of this communication.			
Status						
1)⊠	Responsive to communication(s) filed on 7/1/20	004,6/2/2004.				
		action is non-final.				
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
5)□ 6)⊠ 7)□	Claim(s) 1-17,19-23,25-48 and 50-53 is/are per 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) 1-17,19-23,25-48 and 50-53 is/are rejection(s) is/are objected to.  Claim(s) are subject to restriction and/or	n from consideration.				
Applicati	ion Papers					
9)[	The specification is objected to by the Examiner					
10)[	The drawing(s) filed on is/are: a) acce	pted or b) objected to by the E	xaminer.			
	Applicant may not request that any objection to the d	lrawing(s) be held in abeyance. See	37 CFR 1.85(a).			
—	Replacement drawing sheet(s) including the correction					
11)	The oath or declaration is objected to by the Exa	aminer. Note the attached Office	Action or form PTO-152.			
Priority u	ınder 35 U.S.C. § 119					
a)[	Acknowledgment is made of a claim for foreign p All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau see the attached detailed Office action for a list of	have been received. have been received in Application ty documents have been received (PCT Rule 17.2(a)).	n No d in this National Stage			
Attachment	t(s)					
	e of References Cited (PTO-892)	4) 🔲 Interview Summary (I	PTO-413)			
2) 🔲 Notice	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date	e´.			
) 🔼 Inform Paper	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date <u>12/3/2004</u> .	5)	ent Application (PTO-152)			

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04) Art Unit: 1616

## **DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/1/2004 has been entered.

# **Priority**

Applicant claims priority as a continuation of US Pat. App. 09/619,899. In prior art

Office Actions, Examiner indicated that the present application and Application 09/619,899 did

not appear to contain the same material. Applicant has indicated that it simply redacted material
which it felt was not pertinent to the claimed invention. Examiner respectfully requests that

Applicant provided a marked up copy as to what was changed from the 09/619,899 Specification
so that Examiner can make a comparison of the two Specifications.

# Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-17, 19-23, 25-48, 50-53 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for sildenafil, does not reasonably provide enablement for erectile dysfunction agent. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

The nature of the invention:

Art Unit: 1616

The invention is directed to a composition containing an erectile dysfunction active agent in combination with water-soluble hydrocolloid, and starch graft copolymer.

The state of the prior art and the predictability or lack thereof in the art:

The prior art does not appear to disclose said combination, as such, predictability in the art appears to be low as to suitable erectile dysfunction agents.

The amount of direction or guidance present and the presence or absence of working examples:

Other than sildenafil the Specification does not disclose other erectile dysfunctional active agents, how they may be administrated, whether they can be combined with the carriers or dosage amounts.

The breadth of the claims and the quantity of experimentation needed:

The claims are broad in that the only erectile dysfunctional active agent disclosed is sildenafil. As such, it appears that one of ordinary skill in the art would be required to do undue experimentation in order to determine what other agents would fall within the scope of the limitation "erectile dysfunction active agent", whether they would be compatible or combinable with the carriers and the appropriate route of administration and effective dosage amount.

#### Conclusion

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier number for accessing the facsimile machine is (703) 872-9306.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Choi whose telephone number is (571)272-0610. Examiner maintains a flexible schedule. However, Examiner may generally be reached Monday-Friday, 8:00 am - 5:30 pm (EST), except the first Friday of the each biweek which is Examiner's normally scheduled day off.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Mr. Gary Kunz, can be reached at 571-272-0887. Additionally, Technology Center 1600's Receptionist and Customer Service can be reached at (571) 272-1600.

FIC

September 20, 2004

S. MARK CLARDY
PATENT EXAMINER
GROUP 1200 666